FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3173928032> ?p ?o ?g. }

• W3173928032 endingPage "P" @default.
• W3173928032 startingPage "1010" @default.
• W3173928032 abstract "Introduction: Multiple case studies have reported diabetic ketoacidosis (DKA) in recently-diagnosed cancer patients, especially those taking immune checkpoint inhibitors. The prevalence of DKA and other acute diabetes complications (ADC), including hypoglycemia and hyperosmolarity, and their relationship with the onset of systemic cancer therapy is unclear. Methods: This study utilized data from n=9,588 cancer patients from the Huntsman Cancer Institute, UT. Data on clinicodemographic characteristics, biomarkers, and cancer diagnoses were extracted from electronic medical records (EMR) and tumor registry. Patients included in this analysis received an ICD diagnosis of hypoglycemia, hyperosmolarity with or without coma, and/or DKA with or without coma. Systemic therapy was defined as any chemotherapy, immunotherapy or hormone therapy resulting from a specific first primary cancer diagnosis. Results: There were 243 instances of ADC within this cohort, occurring in 211 (2.2%) unique patients. Of these 211 unique patients with an ADC, 106 (50.0%) experienced their first ADC within one year after cancer diagnosis, with a median time to ADC diagnosis of 88 days. Forty-seven (44%) of these patients experienced the ADC following the onset of systemic therapy, with a median time from systemic therapy onset to ADC diagnosis of 120 days. In these 47 patients who received an ADC diagnosis following the onset of systemic therapy, 40 (85.1%) received chemotherapy (n=20 as monotherapy), 20 (42.6%) received immunotherapy (n=4 as monotherapy) and 12 (25.5%) received hormone therapy (n=2 as monotherapy). Only 54% of patients experiencing an ADC after cancer diagnosis had a history of diabetes prior to cancer, and on average their first diabetes diagnosis was 5.4 ± 4.4 years prior to their cancer diagnosis. Discussion: ADCs may be common following a cancer diagnosis, however a substantial number occurred prior to the onset of systemic cancer therapy and in patients with no prior history of diabetes. Disclosure R. Viskochil: None. S. Hardikar: None. S. Pauleck: None. M. Winn: None. K. Funai: None. M. L. Litchman: Research Support; Self; Abbott Diabetes. W. Akerley: None. H. Colman: Advisory Panel; Self; Adastra Pharmaceuticals, Orbus Therapeutics, Consultant; Self; Best Doctors/Teladoc. C. M. Ulrich: None. M. C. Playdon: None. Funding University of Utah Health/Larry H. Miller Family Wellness Initiative" @default.
• W3173928032 created "2021-07-05" @default.
• W3173928032 creator A5000351254 @default.
• W3173928032 creator A5003317297 @default.
• W3173928032 creator A5009460223 @default.
• W3173928032 creator A5012072182 @default.
• W3173928032 creator A5026284132 @default.
• W3173928032 creator A5028294315 @default.
• W3173928032 creator A5034618262 @default.
• W3173928032 creator A5040217333 @default.
• W3173928032 creator A5053520269 @default.
• W3173928032 creator A5085626501 @default.
• W3173928032 date "2021-06-01" @default.
• W3173928032 modified "2023-09-25" @default.
• W3173928032 title "1010-P: Prevalence of Acute Diabetes Complications following Cancer Diagnosis and Treatment" @default.
• W3173928032 doi "https://doi.org/10.2337/db21-1010-p" @default.
• W3173928032 hasPublicationYear "2021" @default.
• W3173928032 type Work @default.
• W3173928032 sameAs 3173928032 @default.
• W3173928032 citedByCount "0" @default.
• W3173928032 crossrefType "journal-article" @default.
• W3173928032 hasAuthorship W3173928032A5000351254 @default.
• W3173928032 hasAuthorship W3173928032A5003317297 @default.
• W3173928032 hasAuthorship W3173928032A5009460223 @default.
• W3173928032 hasAuthorship W3173928032A5012072182 @default.
• W3173928032 hasAuthorship W3173928032A5026284132 @default.
• W3173928032 hasAuthorship W3173928032A5028294315 @default.
• W3173928032 hasAuthorship W3173928032A5034618262 @default.
• W3173928032 hasAuthorship W3173928032A5040217333 @default.
• W3173928032 hasAuthorship W3173928032A5053520269 @default.
• W3173928032 hasAuthorship W3173928032A5085626501 @default.
• W3173928032 hasConcept C121608353 @default.
• W3173928032 hasConcept C126322002 @default.
• W3173928032 hasConcept C134018914 @default.
• W3173928032 hasConcept C177713679 @default.
• W3173928032 hasConcept C187212893 @default.
• W3173928032 hasConcept C555293320 @default.
• W3173928032 hasConcept C71924100 @default.
• W3173928032 hasConceptScore W3173928032C121608353 @default.
• W3173928032 hasConceptScore W3173928032C126322002 @default.
• W3173928032 hasConceptScore W3173928032C134018914 @default.
• W3173928032 hasConceptScore W3173928032C177713679 @default.
• W3173928032 hasConceptScore W3173928032C187212893 @default.
• W3173928032 hasConceptScore W3173928032C555293320 @default.
• W3173928032 hasConceptScore W3173928032C71924100 @default.
• W3173928032 hasIssue "Supplement 1" @default.
• W3173928032 hasLocation W31739280321 @default.
• W3173928032 hasOpenAccess W3173928032 @default.
• W3173928032 hasPrimaryLocation W31739280321 @default.
• W3173928032 hasRelatedWork W1563850031 @default.
• W3173928032 hasRelatedWork W2032287785 @default.
• W3173928032 hasRelatedWork W2094113608 @default.
• W3173928032 hasRelatedWork W2167444163 @default.
• W3173928032 hasRelatedWork W2233866314 @default.
• W3173928032 hasRelatedWork W2374391052 @default.
• W3173928032 hasRelatedWork W2383009242 @default.
• W3173928032 hasRelatedWork W2415759662 @default.
• W3173928032 hasRelatedWork W3036934084 @default.
• W3173928032 hasRelatedWork W88627568 @default.
• W3173928032 hasVolume "70" @default.
• W3173928032 isParatext "false" @default.
• W3173928032 isRetracted "false" @default.
• W3173928032 magId "3173928032" @default.
• W3173928032 workType "article" @default.